The ARHGDIA Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population derived from the HT29 human colorectal adenocarcinoma cell line, engineered to disrupt the ARHGDIA gene. This loss-of-function model ablates expression of Rho GDP-dissociation inhibitor alpha (RhoGDI??), providing a powerful tool for dissecting Rho family GTPase regulation in intestinal epithelial biology. As a polyclonal knockout product, the cell pool contains heterogeneous editing events across the ARHGDIA locus, enabling population-level studies of gene disruption without clonal bias. The product is supplied as a ready-to-use polyclonal stock suitable for direct expansion and functional assays.
The parental HT29 cell line is a widely employed in vitro model of human colorectal adenocarcinoma, isolated from a primary tumor of a 44-year-old female patient. HT29 cells retain epithelial characteristics, including microvilli, tight junctions, and mucin production, and are commonly used to investigate oncogenic signaling, differentiation, and therapeutic responses. This adherent cell line harbors mutations in APC, TP53, and BRAF (V600E), which render it particularly relevant for studying colorectal cancer progression. The intestinal epithelial origin makes HT29 an appropriate host for examining genes involved in cell polarity, barrier function, and metastatic behavior.
ARHGDIA encodes RhoGDI??, a key regulator that binds and sequesters Rho family GTPases??RhoA, Rac1, and Cdc42??in an inactive GDP-bound state, preventing nucleotide exchange and membrane association. This protein interacts directly with ezrin, radixin, and moesin, linking Rho GTPase control to cortical actin organization. ARHGDIA is regulated upstream by signals from the epidermal growth factor receptor (EGFR), transforming growth factor-beta (TGF-??) receptor, SRC kinase, and integrin-mediated adhesion, while miR-191 post-transcriptionally modulates its expression. Upon ARHGDIA disruption, RhoA, Rac1, and Cdc42 become hyperactive, driving phosphorylation of myosin light chain (MLC) via ROCK, cofilin inactivation, and ARP2/3-mediated actin polymerization. This shifts the actin cytoskeleton toward stress fiber formation, lamellipodia extension, and dynamic focal adhesion turnover, as outlined in the mechanistic summary.
In the HT29 colorectal adenocarcinoma context, ARHGDIA knockout disrupts the balance of Rho GTPase activity, promoting a more migratory and invasive phenotype that mirrors key steps in metastatic dissemination. Loss of RhoGDI?? exerts a multifaceted effect: it enhances cell contractility through RhoA?CROCK?CMLC signaling, promotes protrusive activity via Rac1 and Cdc42, and accelerates focal adhesion disassembly. These changes collectively facilitate epithelial-to-mesenchymal transition (EMT)-like characteristics and may influence response to chemotherapeutic agents. Researchers can use this model to interrogate how integrin signaling pathways??involving ITGB1, focal adhesion kinase (FAK), and PDGFR??are rewired upon ARHGDIA depletion, contributing to our understanding of colorectal cancer progression.
The ARHGDIA Knockout HT29 Polyclonal Cells are suited for a broad spectrum of investigations. Applications include dissecting Rho GTPase signaling cascades, performing transwell migration and Matrigel invasion assays, and assessing cytoskeletal remodeling through immunofluorescence of F?actin and vinculin. The cells enable western blotting for ARHGDIA, RhoA, Rac1, and phospho?MLC, as well as RT?qPCR profiling of EMT markers and Rho GTPase transcripts. Rho GTPase activity can be directly measured via pull?down assays, while co?immunoprecipitation and confocal microscopy facilitate protein interaction studies. This model also supports drug resistance screening and wound?healing assays. For further technical details or order inquiries, please contact Ascent Research.
